An Coosemans
YOU?
Author Swipe
View article: Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside
Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside Open
sponsorship: Janke Kleynhans is supported financially by the Fonds Wetenschappelijk Onderzoek-Vlaanderen (FWO) through a senior postdoctoral grant [1226524 N-7029]. Christophe M Deroose is a Senior Clinical Investigator at the FWO. Thomas …
View article: Circulating tumor DNA in the diagnosis of ovarian cancer: a systematic review
Circulating tumor DNA in the diagnosis of ovarian cancer: a systematic review Open
Although heterogeneity across studies precluded meta-analysis, narrative synthesis suggests that ctDNA may offer an improved early detection capability over CA125, through methylation and copy number variation analyses. Further controlled …
View article: Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors Open
Assessment of Different Neoplasias in the Adnexa (ADNEX) is the best-performing model to estimate the risk of malignancy in ovarian tumors. We assessed the incremental value of serum proteins over ADNEX predictors in an exploratory multice…
View article: [11C]HSP990 PET as a translational tool to investigate the role of Hsp90 in tumours and support the development of Hsp90 therapeutics
[11C]HSP990 PET as a translational tool to investigate the role of Hsp90 in tumours and support the development of Hsp90 therapeutics Open
[11C]HSP990 is a promising tracer for identifying Hsp90-overexpressing tumours and may hold potential for patient stratification, prognosis, and therapy monitoring of novel Hsp90 therapeutics. High healthy brain uptake of this tracer precl…
View article: Exploring the tumor microenvironment in diffuse intrinsic pontine glioma: immunological insights and therapeutic challenges
Exploring the tumor microenvironment in diffuse intrinsic pontine glioma: immunological insights and therapeutic challenges Open
Diffuse intrinsic pontine glioma (DIPG) is a rare and highly aggressive pediatric brain tumor with a median survival of less than 12 months. The tumor arises in the pons, making surgical resection unfeasible and limiting treatment options …
View article: Figure 4 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Figure 4 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
NACT positively increases the ICI-sensitive TCF1+PD1+CD8+ T-cell phenotype within metastatic HGSOC. A, Representative image of immunofluorescence of CD68, CD8, PD-L1, FoxP3, TCF1, CD57, PanCK, PD1, CD4, CD20, GZMB, and TIM-3 staining (immu…
View article: Figure 6 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Figure 6 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
The clinical relevance of combined chemotherapy and immunotherapy in mouse models of TMBLo and TMBHi ovarian cancer. A and B, Bar plots showing single-nucleotide variants positions (SNVs) (A) and the somatic mutations prevalence (mutations…
View article: Figure 5 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Figure 5 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
NACT-mediated progenitor TCF1+PD1+CD8+ T-cell phenotype associates with effector cytotoxic functions within metastatic HGSOC. A–C, Representative dot plot (A) and box plot (B) showing percentage of TIM-3+PD1+CD8+ T cells and GZMB+CD8+ T ce…
View article: Figure 1 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Figure 1 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
Immunomodulation by NACT in metastatic HGSOC. A, Representative images of CALR immunostaining in CALRLo and CALRHi patients. Scale bars, 10 and 100 µm. B, CALR expression levels determined by immunostaining and (C) ER stress signature leve…
View article: Data from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Data from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
Purpose:Patients with high-grade serous ovarian carcinoma (HGSOC) are virtually insensitive to immune checkpoint inhibitors (ICI) employed as standalone therapeutics, at least in part reflecting microenvironmental immunosuppression. Thus, …
View article: Figure 2 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Figure 2 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
NACT-mediated adjuvanticity positively impacts clinically relevant TLS maturation in metastatic HGSOC. A, Representative image of immunofluorescence of CD4, CD8, CD20, CD21, CD23, DC-LAMP, and GZMB staining (immunofluorescence panel 1). Sc…
View article: Table 1 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Table 1 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
Univariate Cox proportional hazard analyses.
View article: Figure 3 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Figure 3 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
NACT-mediated adjuvanticity positively impacts the density of follicular T cells (TFH) and in situ activation of intratumoral B cells in mHGSOC. A–C, Representative image (A) and box plots showing the density of CD4+ cells (B) and CXCR5+PD…
View article: Supplementary Data1 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer
Supplementary Data1 from Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1<sup>+</sup>CD8<sup>+</sup> T Cells in Metastatic Ovarian Cancer Open
Supplemental material, figures and tables
View article: OC21.06: Central necrosis in uterine sarcomas
OC21.06: Central necrosis in uterine sarcomas Open
status: Published
View article: MetDecode: methylation-based deconvolution of cell-free DNA for noninvasive multi-cancer typing
MetDecode: methylation-based deconvolution of cell-free DNA for noninvasive multi-cancer typing Open
Motivation Circulating-cell free DNA (cfDNA) is widely explored as a noninvasive biomarker for cancer screening and diagnosis. The ability to decode the cells of origin in cfDNA would provide biological insights into pathophysiological mec…
View article: Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian Cancer
Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian Cancer Open
Purpose: Patients with high-grade serous ovarian carcinoma (HGSOC) are virtually insensitive to immune checkpoint inhibitors (ICI) employed as standalone therapeutics, at least in part reflecting microenvironmental immunosuppression. Thus,…
View article: Alleviating cell-free DNA sequencing biases with optimal transport
Alleviating cell-free DNA sequencing biases with optimal transport Open
Cell-free DNA (cfDNA) is a rich source of biomarkers for various (patho)physiological conditions. Recent developments have used Machine Learning on large cfDNA data sets to enhance the detection of cancers and immunological diseases. Prean…
View article: Alleviating cell-free DNA sequencing biases with optimal transport
Alleviating cell-free DNA sequencing biases with optimal transport Open
Cell-free DNA (cfDNA) is a rich source of biomarkers for various (patho)physiological conditions. Recent developments have used Machine Learning on large cfDNA data sets to enhance the detection of cancers and immunological diseases. Prean…
View article: Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance Open
Background Ovarian cancer is the leading cause of mortality among gynecological malignancies. Carboplatin and poly (ADP-ribose) polymerase inhibitors (PARPi) are often implemented in the treatment of ovarian cancer. Homologous recombinatio…
View article: Added value of cell-free DNA over clinical and ultrasound information for diagnosing ovarian cancer
Added value of cell-free DNA over clinical and ultrasound information for diagnosing ovarian cancer Open
Background We previously proposed two cfDNA-based scores (genome-wide z-score and nucleosome score) as candidate non-invasive biomarkers to further improve pre-surgical diagnosis of ovarian malignancy. We aimed to investigate the added val…
View article: Central necrosis in uterine sarcoma
Central necrosis in uterine sarcoma Open
sponsorship: No Statement Available
View article: Alleviating cell-free DNA sequencing biases with optimal transport
Alleviating cell-free DNA sequencing biases with optimal transport Open
Cell-free DNA (cfDNA) is a rich source of biomarkers for various (patho)physiological conditions. Recent developments have used Machine Learning on large cfDNA data sets to enhance the detection of cancers and immunological diseases. Prean…
View article: Editorial: Challenges associated with identifying preclinical animal models for the development of immune-based therapies
Editorial: Challenges associated with identifying preclinical animal models for the development of immune-based therapies Open
status: Published
View article: Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors Open
Background The ADNEX model (Assessment of Different NEoplasias in the adnexa) is the best performing model to predict the risk of malignancy (binary) and type of malignancy (multiclass) in ovarian tumors. The immune system plays a role in …
View article: TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice
TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice Open
Immune checkpoint inhibitor (ICI) therapy has proven revolutionary in the treatment of some cancers. However, ovarian cancer remains unresponsive to current leading ICIs, such as anti-PD1 or anti-PD-L1. In this article, we explored the pot…
View article: P02.08 Immune-related protein changes due to standard of care therapy in recurrent ovarian cancer patients
P02.08 Immune-related protein changes due to standard of care therapy in recurrent ovarian cancer patients Open
Background High-grade serous ovarian cancer has a recurrence and mortality rate of approximately 80%. The impact of disease recurrence on the immune system remains unclear. Understanding this could potentially enhance our future therapeuti…